Benitec Biopharma Files 8-K with Financials
Ticker: BNTC · Form: 8-K · Filed: Oct 8, 2024 · CIK: 1808898
Sentiment: neutral
Topics: financial-statements, exhibits, sec-filing
TL;DR
Benitec Biopharma filed an 8-K with financial statements and exhibits. No major news, just paperwork.
AI Summary
On October 8, 2024, Benitec Biopharma Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential updates or disclosures related to the company's financial health and operations. No specific material events or transactions were detailed in the provided excerpt.
Why It Matters
This filing provides an update on Benitec Biopharma's financial statements and exhibits, which could offer insights into the company's financial performance and operational status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting financial statements and exhibits, with no immediate indication of significant positive or negative developments.
Key Players & Entities
- Benitec Biopharma Inc. (company) — Registrant
- 0001193125-24-234458 (document_id) — Accession Number
- October 8, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 3940 Trust Way, Hayward, California 94545 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Benitec Biopharma Inc.?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION' section.
On what date was this 8-K report filed?
The report was filed on October 8, 2024.
What is Benitec Biopharma Inc.'s state of incorporation?
Benitec Biopharma Inc. is incorporated in Delaware.
Where are Benitec Biopharma Inc.'s principal executive offices located?
The principal executive offices are located at 3940 Trust Way, Hayward, California 94545.
Does this filing announce any specific material events or transactions?
Based on the provided excerpt, the filing is categorized under 'Other Events' and 'Financial Statements and Exhibits', and does not explicitly detail any specific material events or transactions.
Filing Stats: 685 words · 3 min read · ~2 pages · Grade level 11.7 · Accepted 2024-10-08 16:45:29
Key Financial Figures
- $0.0001 B — ich registered Common Stock, par value $0.0001 BNTC The Nasdaq Stock Market LLC Indic
- $0.0001 — f the Company's common stock, par value $0.0001 per share, issuable upon the exercise o
- $1.9299 — tember 15, 2022 at an exercise price of $1.9299 per share, (ii) 5,181,347 of the Compan
- $3.86 — August 11, 2023 at an exercise price of $3.86 per share, and (iii) 1,368,180 pre-fund
- $21,135,373 — for aggregate proceeds of approximately $21,135,373. Following the completion of the abov
Filing Documents
- d878957d8k.htm (8-K) — 27KB
- d878957dex991.htm (EX-99.1) — 15KB
- 0001193125-24-234458.txt ( ) — 161KB
- bntc-20241008.xsd (EX-101.SCH) — 3KB
- bntc-20241008_lab.xml (EX-101.LAB) — 17KB
- bntc-20241008_pre.xml (EX-101.PRE) — 11KB
- d878957d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Letter Agreement, dated as of September 26, 2024, by and between the Company and Suvretta Capital Management, LLC 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BENITEC BIOPHARMA INC. Date: October 8, 2024 By: /s/ Jerel A. Banks Name: Jerel A. Banks Title: Chief Executive Officer